JPH08252308A - Medical material and its manufacture - Google Patents

Abstract

PURPOSE: To facilitate the manufacture, uniformly contain an antiplatelet agent, and continuously release the antiplatelet agent by mixing the antiplatelet agent in a polyester block copolymer consisting of a polyester as hard segment and a soft segment. CONSTITUTION: An antiplatelet agent is contained in a polyester block copolymer consisting of a polyester as hard segment and a soft segment to form a medical material. As the polyester block copolymer, a block copolymer consisting of polyester and polyether is used. As the polyester block copolymer, further, a block copolymer consisting of polyester as hard segment and a polyester of a kind differed from it is used. This medical material has loss preventing effect of platelet since the antiplatelet agent can be contained in the uniformly and stably dispersed state, and the antiplatelet agent can be continuously eluted in an effective concentration.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medical material in the medical field, particularly for forming a medical device which comes into direct contact with blood, and a method for producing the same. More particularly, it relates to blood coagulation even in direct contact with blood. The present invention relates to a medical material that does not cause (thrombus formation) or loss of platelets and a method for producing the same.

[0002]

2. Description of the Related Art In the medical field, thrombus formation of a polymeric material used in blood circuits, bypass tubes, catheters, etc. that come into direct contact with blood has become an important issue. Therefore, provision of a medical material having excellent anticoagulant or antithrombotic properties has been desired. Conventionally, methods for imparting antithrombogenicity to medical materials include, for example, (1) complexing heparin, which is an anticoagulant, with a polymer material, or (2) applying a fibrinolytic enzyme to the surface of the polymer material. There is known a method of immobilizing the same on the surface of the surface (for example, JP-A-54-68097 (Japanese Patent Publication No. 60-
40861), JP-A-56-136564 (JP-B-59-51304), JP-A-57-75.
Japanese Patent Publication No. 655 (Japanese Patent Publication No. 61-6662) and Japanese Patent Laid-Open Publication No. 57-14358 (Japanese Patent Publication No. 63-43107)].

However, the above method (1) has great restrictions on processing and manufacturing because heparin is unstable to heat, and is expected to have long-term sustainability because the amount of heparin retained in the material is small. There are problems such as not being able to. Further, in the method of (2), the processing method is surface coating and the processing method is complicated, and the fibrinolytic activity is easily impaired by heat. There is a problem that the absolute amount of fibrinolytic enzyme in the inside is small and sustainability cannot be expected.

In addition, the safety of the chemical structure used as a ligand or a spacer in complexing and immobilizing these substances to the human body has not been completely clarified. On the other hand, materials having excellent blood compatibility have been developed so as not to cause thrombus. In the field of artificial blood vessels, for example, polytetrafluoroethylene stretched structure artificial blood vessels manufactured by Gore in the United States are known. However, in order to develop antithrombotic properties with these materials, it is essential to have a porous structure by stretching,
The restrictions on the use and manufacturing method increase.

[0005] Further, medical materials of polyurethane or polyurethaneurea having a micro phase separation structure are also known. However, since the thermoforming is difficult, the manufacturing process is complicated and the manufacturing restrictions are large. There is a problem that the structure changes greatly depending on the processing method, and it is difficult to obtain a constant antithrombotic property. Furthermore, medical materials in which an antiplatelet agent is mixed with polyurethane or polyurethaneurea have been proposed, but the manufacturing process is complicated because thermoforming is difficult,
There is a problem that there are large manufacturing restrictions.

On the other hand, a (2-hydroxyethylmethacrylate) -styrene copolymer having a microphase-separated structure is known to have antithrombogenicity, but since it has low mechanical strength, it is used as a coating material. The field of use is limited to a small part. Furthermore, there has been proposed a medical material in which a thermoplastic polymer such as polyester or polyamide having a microphase-separated structure is mixed with a proteolytic enzyme inhibitor such as nafamostat mesylate or gavexate mesylate (JP-A-6-23032). However, these proteolytic enzyme inhibitors generally have extremely high water solubility and are rapidly lost from the vicinity of the surface of the material, making it difficult to maintain long-term sustained antithrombotic properties, Not practical.

The main object of the present invention is to solve the above technical problems, to facilitate the production, to allow the antiplatelet agent to be uniformly contained therein, and to enable the sustained release of the antiplatelet agent. To provide a medical material and a manufacturing method thereof.

[0008]

[Means for Solving the Problems] As a result of various studies on the conjugation of various drugs with a polymeric material in order to solve the above problems, the present inventors have found that antiplatelet agents, particularly cilostazol, dipyridamole, Aspirin and the like can be contained in a specific polyester block copolymer in a uniform and stable dispersion state, and further, the type of the copolymer, the content of the antiplatelet agent, the method for containing the copolymer, and the copolymer described above. The present invention has been completed by discovering a new fact that the release rate of an antiplatelet agent can be arbitrarily controlled depending on the formulation of additives to be added to the composition.

That is, the medical material of the present invention is characterized by containing an antiplatelet agent in a polyester block copolymer comprising polyester as a hard segment and a soft segment. Further, the method for producing a medical material of the present invention is characterized in that a polyester block copolymer comprising polyester as a hard segment and a soft segment is mixed with an antiplatelet agent in a molten state.

Another method for producing a medical material of the present invention is to dissolve a polyester block copolymer consisting of polyester as a hard segment and a soft segment and an antiplatelet agent in a solvent, mix them, and then add the solvent. It is characterized by being removed.

[0011]

BEST MODE FOR CARRYING OUT THE INVENTION The medical material of the present invention will be described in detail below. The above polyester block copolymers include block copolymers of polyesters and polyethers, block copolymers of polyesters as hard segments and polyesters of a different type from them, etc., both of which are used in the present invention. can do.

As a specific example thereof, polyester as a hard segment is polycondensed with at least one glycol selected from ethylene glycol, propylene glycol, trimethylene glycol and tetramethylene glycol and terephthalic acid and / or isophthalic acid. There are things that are things. Further, the polyester block copolymer of the present invention has, for example, formulas (1) to (3):

[0013]

[Chemical 7]

[0014]

Embedded image

[0015]

[Chemical 9]

Examples thereof include those having a structural formula represented by the formula (A represents a chain extender residue). More specifically, the polyester block copolymer of the present invention is, as a commercial product, a product name “Hytrel” manufactured by Toray-Dupont, a product name “Perprene P” manufactured by Toyobo Co., Ltd., and a product name “Perprene” manufactured by the same company. S ", Japan GE Plastics' trade name" Romod ", Enimont-Nippon Synthetic Rubber Co., Ltd.'s trade name" Piviflex ", Dainippon Ink's trade name" Grelax E ", Eastman's The trade name is "Ecter", the trade name is "Lightflex" from Hoechst Celanese, the trade name is "Elastafu" from Goodyear, and the trade name is "Arnitel S" from Akzo.

Further, the polyester block copolymer used in the medical material of the present invention may have various physical properties depending on the purpose and application. For example, the chain length and the degree of polymerization of the hard segment and the soft segment, the degree of polymerization of the entire copolymer, the content ratio of the hard segment and the soft segment can be appropriately selected from a wide range, among them,
Those having a Shore hardness of 75 A to 75 D can be preferably used. In addition, if necessary, plasticizers such as di-2-ethylhexyl phthalate, di-2-decyl phthalate and tri-2-ethylhexyl trimellitate, various stabilizers, secondary plasticizers, lubricants, and ultraviolet absorbers. , A colorant and the like can be added and blended.

These polyester block copolymers may be used alone, or two or more kinds may be mixed or laminated and combined. Examples of the antiplatelet agent in the present invention include cilostazol, dipyridamole, aspirin, ticlopidine, beraprost, indomethacin, sulfinpyrazone, satigrel, d-indobufen, dazoxiben, flegrelate, ozagrel, permagrel, dazmegrel, midazogrel, daltroban, sulotroban, vapiprost, Examples include clopidogrel, prostaglandin E ₁ , iloprost, limaprost, and the like. Besides these, 2- [4,5-bis (4-methoxyphenyl) thiazol-2-yl] pyrrole-1-acetic acid ethyl ester, 2- Methyl-3-
(1,4,5,6-Tetrahydronicotinoyl) pyrazolo [1,5-a] pyridine, 1- (cyclohexylmethyl) -4- [4- (2,3-dihydro-2-oxo-1)
H-imidazo [4,5-b] quinolin-7-yloxy) -1-oxobutyl] piperazine, 3-methyl-2
-(3-Pyridinyl) -1H-indole-1-octanoic acid, (E) -7-phenyl-7- (3-pyridyl)-
6-Heptenoic acid, (±) -6- (1-imidazolylmethyl) -5,6,7,8-tetrahydronaphthalene-2-
Carboxylic acid, 4- [α-hydroxy-5- (1-imidazolyl) -2-methylbenzyl] -3,5-dimethylbenzoic acid, 1- (2-carboxyethyl) -2-methyl-
3- (1H-imidazol-1-ylmethyl) indole, (E) -1- [3- (phenylmethoxy) -1-octenyl] -1H-imidazole, 7- [2α, 4α-
(Dimethylmethano) -6β- (2-cyclopentyl-2
β-Hydroxyacetamide) -1α-cyclohexyl]
-5 (Z) -heptanoic acid, (E) -11- [2- (5,
6-Dimethyl-1-benzimidazolyl) ethylidene]
-6,11-Dihydrodibenz [b, e] oxepin-
2-carboxylic acid, 5-{(1R, 6S, 7S, 8R)-
8-hydroxy-7-[(3S) -3-hydroxy-
4,4-Dimethyl-1,6-nonadiynyl] -cis-bicyclo [4,3,0] non-2-en-3-yl} -3
-Oxapentanoic acid, 5-{(1S, 5S, 6R, 7
R) -7-Hydroxy-6-[(E)-(S) -3-hydroxy-1-octenyl] bicyclo [3,3,0] oct-2-en-3-yl} pentanoic acid methyl ester, [ 1α, 2α (Z), 3β, 4α]-(±) -7-
{3-[(phenylsulfonyl) amino] -bicyclo [2,2,1] hept-2-yl} -5-heptenoic acid,
(-)-Cis-3-acetoxy-5- [2- (diethylamino) ethyl] -2,3-dihydro-8-methyl-2
Examples thereof include-(4-methylphenyl) -1,5-dibenzothiazepin-4- (5H) -one. Moreover, these can be used individually or in mixture of 2 or more types. Of the above examples, it is preferable to use cilostazol, dipyridamole, beraprost, satiglel, and aspirin, and it is particularly preferable to use cilostazol.

In the present invention, the antiplatelet agent is blended in an amount of 0.01 to 60 parts by weight, preferably 0.01 to 45 parts by weight, and more preferably 0.005 parts by weight, based on 100 parts by weight of the polyester block copolymer. It is in the range of 05 to 10 parts by weight, more preferably 0.1 to 6 parts by weight. If the content of the antiplatelet agent exceeds this range, the moldability becomes poor, and even if molding is possible, the physical properties may be deteriorated and problems may occur in practical use. On the other hand, if the content of the antiplatelet agent is less than the above range, it may be difficult to control the release of the antiplatelet agent, and the anticoagulant effect may be lowered.

Further, as will be described later, the release amount of the antiplatelet agent can be controlled by changing the content of the antiplatelet agent within the above range. In general, the amount of the antiplatelet agent uniformly dispersed in the polyester block copolymer has an upper limit, but if it is in the range up to the upper limit amount, the higher the content, the faster the release rate of the antiplatelet agent. Become. On the other hand, when the antiplatelet agent is contained in a large amount in excess of the above upper limit amount, the release amount is rather reduced, but the duration is expected to be extended by that amount. Therefore, it is desirable to determine an appropriate content of the antiplatelet agent according to the type, purpose, application, etc. of the medical material to be formed.

In the present invention, the polyester block copolymer containing the antiplatelet agent may be used as it is as a main constituent material of a medical material, or may be used by coating (impregnating) or impregnating it with another material. You may.
The medical material of the present invention can be suitably used, for example, as a material for medical instruments. Examples of such medical instruments include temporary bypass tubes for vascular surgery, cannulas, monitoring tubes, blood circuits for artificial dialysis, catheters for artificial dialysis, artificial lungs, artificial hearts, blood circuits for extracorporeal circulation, A- for artificial kidneys. Examples include V shunts, artificial blood vessels, stents, blood bags, disposable circuits for blood component separation devices, intravenous indwelling needles, and catheters.

Next, a method for manufacturing the medical material of the present invention and a device using the medical material of the present invention will be described. Typical manufacturing methods include a solution method and a melting method. In the solution method, the polyester block copolymer and the antiplatelet agent are uniformly dissolved in a solvent, and then the solvent is distilled off to obtain the medical material of the present invention. Examples of the solvent include chloroform, ethane tetrachloride, phenol,
Orthochlorophenol, metacresol, dichloromethane, 1,1,1,3,3,3-hexafluoro-2-
Examples thereof include propanol and a mixed solvent of two or more kinds of these. Of these, chloroform, dichloromethane, ethane tetrachloride, 1,1,1,3,3,3-hexafluoro-2-propanol and the like are particularly preferable because of their high solubility and easy distillability.

It is preferable that the polyester block copolymer used is thoroughly washed in advance by Soxhlet extraction or the like to remove impurities and the like. Further, it is sufficiently dried under conditions that do not cause oxidative decomposition to remove water. It is also preferable to keep it. Molding of medical materials by the solution method is to cast the solution prepared by dissolving each of the above components in a solvent onto a glass plate, or extrude it into a tube, or apply it to another structure, and then remove the solvent. Done by. This makes it possible to form a film, a tube, or the like into a desired shape, or to perform coating, depending on the application of the medical material.

The solvent is removed by, for example, air drying, heat drying under reduced pressure, phase separation with a coagulating liquid, or the like. Examples of the coagulating liquid include poor solvents for the polyester block copolymer, for example, water, alcohols such as methanol, ethanol, propanol and butanol, and ketones such as acetone. In this case, it is necessary to avoid elution of the antiplatelet agent from the aggregate of the copolymer into the coagulation liquid as much as possible. Therefore, when the solubility of the antiplatelet agent in the poor solvent of the copolymer is large, a solvent that reduces the solubility of the antiplatelet agent in the poor solvent of the resin is mixed as a coagulating solution into the coagulating solution, It is preferable to adopt a method in which the antiplatelet agent contained therein and the antiplatelet agent contained therein are coagulated at the same time.

The case of forming a tubular device by the solution method will be described in detail. A solution prepared by dissolving each of the above components in a solvent is applied to the surface of an appropriate mandrel and dried to form a tube. Get out of the mandrel. Also,
Alternatively, the solution is applied to the surface of the mandrel, which is then immersed in a coagulating liquid to coagulate the polymer on the surface of the mandrel to form a tube, and then the tube is removed from the mandrel and dried. Alternatively, a method may be mentioned in which the solution is extruded into a coagulating solution in a hollow form and then dried. Furthermore, by dipping method, decompression method, gas pressure feeding method, in existing equipment such as bypass tube, blood circuit, blood circuit for artificial dialysis,
It can also be manufactured by a coating method such as a rotating drum method.

When a film-shaped material is formed by the solution method, for example, the solution is cast on a glass plate to remove the solvent by drying, or the solution is directly coated or impregnated on a woven fabric, a knitted fabric, a non-woven fabric or the like. Examples of the method include a method in which the solvent is dried and removed and then formed into a film.
Further, it can be produced by coating an existing film by a dipping method, a spraying method or the like. Further, the film obtained by the above method may be further coated to form a multilayer film.

In the solution method, the release rate of the antiplatelet agent from the molded article is controlled by controlling the content of the antiplatelet agent in the polyester block copolymer, the type of antiplatelet agent used, the polyester block copolymer, and the like. Composition (constituent components and ratio of each segment), solvent removal method (for example,
Drying under normal pressure or reduced pressure, or a method of coagulating using a coagulating liquid) and the like can be performed. In addition, the release rate can be controlled also by a compounding formulation of additives such as a plasticizer, a stabilizer, a secondary plasticizer, a lubricant, an ultraviolet absorber and a heat resistance stabilizer. In the case of coating, the coating is repeated multiple times, and the type of copolymer, concentration of drug,
It is also possible to perform more detailed release control by changing the conditions such as the content.

The above-mentioned solution method is useful especially when a drug which is unstable to heat is used among the antiplatelet agents. On the other hand, in the case of the melting method, the medical material of the present invention can be obtained by mixing the polyester block copolymer and the antiplatelet agent in a molten state and molding the mixture. The melting should ensure that the antiplatelet agent is uniformly dispersed in the polyester block copolymer without degradation. Therefore, an appropriate polyester block copolymer and antiplatelet agent that melt at a temperature equal to or lower than the decomposition temperature of the antiplatelet agent are selected and used. It should be noted that, if necessary, operations such as melting and molding can be carried out in an oxygen-free atmosphere to prevent oxidation of the antiplatelet agent and the polyester block copolymer. Further, it is preferable to remove as much water as possible from the polyester block copolymer to be used, from the viewpoints of the stability of the drug or the copolymer, the dimensional accuracy of the molded product, the appearance, and the like.

Various molding methods can be used for the melt molding. For example, a tube-shaped or sheet-shaped molded product can be molded by extrusion molding, and a molded product having a complicated structure can be molded by injection molding. Further, by using a cross head or the like, it is possible to coat a metal wire. Regarding the release control of the antiplatelet agent from the molded product in the melt molding, the content of the antiplatelet agent in the polyester block copolymer, the type of the antiplatelet agent used, the type of the polyester block copolymer, etc. are changed. Can be done by Further, similarly to the solution method, it is possible to control the release rate of the antiplatelet agent by blending the additives such as a plasticizer, a stabilizer, a secondary plasticizer and a lubricant. Furthermore, by performing multi-layer (multi-color) molding and changing the content and type of antiplatelet agent and the type of copolymer in each layer (portion), it is possible to obtain the required physical properties as a medical material and It is possible to express anticoagulant properties only by itself and to control the release pattern more finely.

In the present invention, a particularly preferable combination is that the antiplatelet agent is cilostazol and the resin is a polyether polyester copolymer, and cilostazol has excellent compatibility with the polyether polyester block copolymer. , Can be mixed uniformly. Among the materials of the present invention, those formed into a tube shape are particularly suitably used as a blood circuit for extracorporeal circulation, a catheter, a bypass tube and the like. Further, by molding using a multi-layer die, it is possible to easily manufacture multi-layer tubes having different compositions.

When the medical material of the present invention formed into a tubular shape is used in an extracorporeal circulation circuit in open heart surgery,
When cilostazol, dipyridamole, etc. are used as the antiplatelet agent to be contained, not only the anticoagulant effect but also the vasodilatory effect is exerted, so that the circulatory failure of peripheral tissues due to controlled shock can be improved, which is more convenient. .

The film-shaped medical material of the present invention can be suitably used as a material for blood bags and the like. Among them, a film formed by using a material having a large gas permeability such as an ethylene-vinyl acetate copolymer or an ethylene-α-olefin copolymer is particularly suitable as a platelet storage bag. Examples of using the medical material of the present invention as a medical device are not limited to the above-mentioned examples, for example, the medical material of the present invention molded into an arbitrary shape is used as a member for exhibiting an antiplatelet effect. It is also possible to use it by installing it in a medical device. Also,
A method of encapsulating a small piece of the medical material of the present invention formed into a film shape, a granular shape, or the like in an existing platelet storage bag, and fixing the small piece of the medical material of the present invention at an arbitrary position in the extracorporeal circulation circuit. You can list the ways to do it.

In the medical material of the present invention, the release rate of the antiplatelet agent is controlled by the type and amount of the antiplatelet agent, the method for containing the same, the type of polyester block copolymer, the formulation of additives, etc., as described above. However, it is also possible to control the release rate by varying the shape to be molded, in particular the surface area.

[0034]

The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples. Example 1 Hytrel 4057 (trade name of Toray DuPont)
Cooled and pulverized with a small pulverizer (made by Inei Seieidou) to obtain a particle size of 5
Those having a thickness of 0 to 125 μm were collected. Of these, 38 g and cilostazol (manufactured by Otsuka Pharmaceutical Co., Ltd.) 2 g were dry blended, and a small kneading extruder (trade name “CS-1 manufactured by CSI”)
94A, MAXMIXING EXTRUDER "), and kneaded and extruded at 190 ° C in a nitrogen atmosphere, and immediately after extrusion, 190 ° C by a test bench press (manufactured by Toyo Seiki Co., Ltd.)
Then, it was hot-pressed to obtain a colorless film having a thickness of 100 μm. Example 2 (Preparation of catheter) Hytrel 4057 (trade name of Toray DuPont)
Cooled and pulverized with a small pulverizer (made by Inei Seieidou) to obtain a particle size of 5
Those having a thickness of 0 to 125 μm were collected. Of these, 38 g and cilostazol (manufactured by Otsuka Pharmaceutical Co., Ltd.) 2 g were dry-blended, and kneaded and extruded at 190 ° C. under a nitrogen atmosphere using a strand kneading extruder using a small kneading extruder (manufactured by CSI, the same as above), Pelletized. This is again extruded by a small kneading extruder (manufactured by CSI, same as above) at 190 ° C. in a nitrogen atmosphere using a tube die to produce a tube having an inner diameter of 0.8 mm and an outer diameter of 1.0 mm. did. Example 3 Hytrel 4057 (described above) was cooled and pulverized by a small pulverizer (manufactured by Inai Seieidou) to obtain particles having a particle diameter of 50 to 125 μm. Of these, 39.92 g and cilostazol (Otsuka Pharmaceutical Co., Ltd.) 0.08 g were dry blended,
A small kneading extruder (manufactured by CSI, same as above) is kneaded and extruded at 190 ° C. in a nitrogen atmosphere, and immediately after extrusion, hot pressed at 190 ° C. by a test bench press (manufactured by Toyo Seiki Co., Ltd.) to give a 100 μm thick colorless product. I got a film of.

Since the content of cilostazol in this film is smaller than that in the film of Example 1, the dissolution rate is suppressed. Further, the dispersion stability of cilostazol in the resin is excellent, and it is useful as a medical material that can be stored or used for a long period of time. (Dissolution test) 100 mg of the film obtained in Example 1 was sampled and put into 10 ml of a physiological saline solution having a pH of 7.4 that had been preheated to 37 ° C, and shaken at 37 ° C with a constant temperature shaker. After shaking for 1 hour, the test piece was taken out and another pH was heated to 37 ° C.
It was put into the physiological saline solution of 7.4 and shaken at 37 ° C. for 1 hour with a constant temperature shaker. Hereinafter, this operation was repeated up to 8 hours, and the change in the cilostazol concentration in the eluate at each time was examined.

As a result, as shown in FIG. 1, continuous elution of cilostazol exceeding the effective concentration (1.1 μg / ml) was observed from the initial elution to 8 hours later. Therefore, it can be seen that the film of Example 1 has a high anticoagulant property.

[0037]

INDUSTRIAL APPLICABILITY The medical material of the present invention can contain an antiplatelet agent in a uniform and stable dispersed state.
Further, since such an antiplatelet agent can be eluted continuously and at an effective concentration, it has an effect of having a high anticoagulant property and an effect of preventing platelet loss due to activation of platelets. Furthermore, the method for producing a medical material of the present invention,
The material can be easily manufactured.

[Brief description of drawings]

FIG. 1 is a graph showing changes over time in the concentration of dissolved drug obtained using the film obtained in Example 1.

 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Minoru Yamato Minoru Yamato 9 at 104 Aoki, Otoze, Aizumi-cho, Itano-gun, Tokushima Prefecture (72) Inventor Rika Higashino 1-3 minutes, Shinki-rai, Kitajima-cho, Itano-gun, Tokushima Prefecture

Claims (20)

[Claims] 1. A medical material characterized by containing an antiplatelet agent in a polyester block copolymer comprising a polyester as a hard segment and a soft segment. 2. The medical material according to claim 1, wherein the polyester block copolymer is a block copolymer of polyester and polyether. 3. The medical material according to claim 1, wherein the polyester block copolymer is a block copolymer of polyester as a hard segment and a different type of polyester. 4. A polyester as a hard segment in a polyester block copolymer, wherein the polyester is at least one glycol selected from the group consisting of ethylene glycol, propylene glycol, trimethylene glycol and tetramethylene glycol, and terephthalic acid and / or isophthalic acid. The medical material according to claim 2 or 3, which is a polycondensation product with an acid. 5. A polyester block copolymer having the formula (1)
~ (3): [Chemical formula 1] Embedded image Embedded image The medical material according to claim 4, which is represented by the formula (A represents a chain extender residue). 6. The medical material according to claim 1, wherein the content of the antiplatelet agent is 0.01 to 60 parts by weight with respect to 100 parts by weight of the polyester block copolymer. 7. The medical material according to claim 6, wherein the content of the antiplatelet agent is 0.01 to 45 parts by weight with respect to 100 parts by weight of the polyester block copolymer. 8. The medical material according to claim 7, wherein the content of the antiplatelet agent is 0.05 to 10 parts by weight with respect to 100 parts by weight of the polyester block copolymer. 9. The medical material according to claim 8, wherein the content of the antiplatelet agent is 0.1 to 6 parts by weight based on 100 parts by weight of the polyester block copolymer. 10. The medical material according to claim 1, wherein the antiplatelet agent is at least one selected from the group consisting of cilostazol, dipyridamole, beraprost, and satiglel. 11. The medical material according to claim 10, wherein the antiplatelet agent is cilostazol. 12. The medical material according to any one of claims 1 to 11, which is a medical device material. 13. A method for producing a medical material, which comprises mixing a polyester block copolymer composed of polyester as a hard segment and a soft segment with an antiplatelet agent in a molten state. 14. A polyester block copolymer comprising polyester as a hard segment and a soft segment, and an antiplatelet agent are dissolved in a solvent and mixed,
A method for producing a medical material, which comprises removing a solvent. 15. The method for producing a medical material according to claim 13 or 14, wherein the polyester block copolymer is a block copolymer of polyester and polyether. 16. The polyester block copolymer is a block copolymer of a polyester as a hard segment and a polyester of a different type from the hard segment.
The method for producing a medical material according to 3 or 14. 17. A polyester as a hard segment in a polyester block copolymer, wherein the polyester is at least one glycol selected from the group consisting of ethylene glycol, propylene glycol, trimethylene glycol and tetramethylene glycol, and terephthalic acid and / or isophthalic acid. A polycondensation product with an acid.
The method for producing a medical material according to 5 or 16. 18. A polyester block copolymer having the formula:
(1) to (3): [Chemical formula 4] Embedded image [Chemical 6] The method for producing a medical material according to claim 17, which is represented by the formula (A represents a chain extender residue). 19. The method for producing a medical material according to claim 13, wherein the antiplatelet agent is at least one selected from the group consisting of cilostazol, dipyridamole, beraprost and satiglel. 20. The method for producing a medical material according to claim 19, wherein the antiplatelet agent is cilostazol.